Treatment Details – 14.0 months
|Patients: This phase II study involved seventy-six patients with malignant pleural mesothelioma. The median age was 65, ranging from 40 to 75 years. The majority, 71%, were men.|
Treatment: All patients were treated with the chemotherapy drugs carboplatin and pemetrexed.
Toxicity: Grade 4 hematological toxicities were reported in 5 patients. These were anemia, thrombocytopenia, and neutropenia. Grade 3 toxicities included hematological toxicities, gastrointestinal, mucositis, diarrhea, astenia, fever, and conjunctivitis.
Results: The median overall survival was 14 months, ranging from 1.8 to over 33 months.
Correspondence: Dr. M. Mencoboni